OA10791A - Vaccines against infections caused by yf virus yf infectious cdna method for producing a recombinantyf virus from the yf infectious cdna and plasmids to assemble the yf infectious cdna - Google Patents

Vaccines against infections caused by yf virus yf infectious cdna method for producing a recombinantyf virus from the yf infectious cdna and plasmids to assemble the yf infectious cdna Download PDF

Info

Publication number: OA10791A
Authority: OA; OAPI
Prior art keywords: virus; cdna; infectious cdna; recombinant; infectious
Prior art date: 1997-04-11

Application number

OA9800041A

Other languages

English (en)

Inventor

Ricardo Galler

Marcos Da Silva Freire

Original Assignee

Fundacoa Oswaldo Cruz Fiocruz

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-11

Filing date

1998-04-09

Publication date

2002-12-24

1998-04-09 Application filed by Fundacoa Oswaldo Cruz Fiocruz filed Critical Fundacoa Oswaldo Cruz Fiocruz

2002-12-24 Publication of OA10791A publication Critical patent/OA10791A/en

Links

241000700605 Viruses Species 0.000 title claims abstract description 101
229960005486 vaccine Drugs 0.000 title claims abstract description 67
208000015181 infectious disease Diseases 0.000 title claims abstract description 63
239000013612 plasmid Substances 0.000 title claims abstract description 56
230000002458 infectious effect Effects 0.000 title claims abstract description 49
238000004519 manufacturing process Methods 0.000 title claims abstract description 37
239000002299 complementary DNA Substances 0.000 claims abstract description 74
239000000203 mixture Substances 0.000 claims abstract description 12
210000004027 cell Anatomy 0.000 claims description 26
241000282414 Homo sapiens Species 0.000 claims description 20
238000000034 method Methods 0.000 claims description 16
241000287828 Gallus gallus Species 0.000 claims description 15
241000282693 Cercopithecidae Species 0.000 claims description 14
239000012297 crystallization seed Substances 0.000 claims description 14
210000003734 kidney Anatomy 0.000 claims description 11
210000001161 mammalian embryo Anatomy 0.000 claims description 9
210000002950 fibroblast Anatomy 0.000 claims description 6
239000013598 vector Substances 0.000 claims description 6
238000004113 cell culture Methods 0.000 claims description 5
241000282412 Homo Species 0.000 claims description 4
241000701959 Escherichia virus Lambda Species 0.000 claims description 3
241001524679 Escherichia virus M13 Species 0.000 claims description 3
208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
239000003381 stabilizer Substances 0.000 claims description 3
201000009030 Carcinoma Diseases 0.000 claims description 2
241000282552 Chlorocebus aethiops Species 0.000 claims description 2
208000007128 adrenocortical carcinoma Diseases 0.000 claims description 2
210000003679 cervix uteri Anatomy 0.000 claims description 2
210000002808 connective tissue Anatomy 0.000 claims description 2
108020004705 Codon Proteins 0.000 claims 3
125000003275 alpha amino acid group Chemical group 0.000 claims 3
238000011194 good manufacturing practice Methods 0.000 claims 2
241000283973 Oryctolagus cuniculus Species 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000003306 harvesting Methods 0.000 claims 1
208000003152 Yellow Fever Diseases 0.000 description 99
108091032973 (ribonucleotides)n+m Proteins 0.000 description 36
230000035772 mutation Effects 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
230000003612 virological effect Effects 0.000 description 20
239000012634 fragment Substances 0.000 description 18
150000001413 amino acids Chemical class 0.000 description 17
101710144121 Non-structural protein 5 Proteins 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 15
229940024606 amino acid Drugs 0.000 description 14
241000209094 Oryza Species 0.000 description 13
235000007164 Oryza sativa Nutrition 0.000 description 13
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
235000009566 rice Nutrition 0.000 description 13
241000710831 Flavivirus Species 0.000 description 12
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
238000001890 transfection Methods 0.000 description 11
101710204837 Envelope small membrane protein Proteins 0.000 description 10
101710145006 Lysis protein Proteins 0.000 description 10
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
238000002255 vaccination Methods 0.000 description 10
230000029087 digestion Effects 0.000 description 9
230000002068 genetic effect Effects 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
230000001018 virulence Effects 0.000 description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
229930024421 Adenine Natural products 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000710842 Japanese encephalitis virus Species 0.000 description 6
229960000643 adenine Drugs 0.000 description 6
229940104302 cytosine Drugs 0.000 description 6
235000013601 eggs Nutrition 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 5
208000001490 Dengue Diseases 0.000 description 5
206010012310 Dengue fever Diseases 0.000 description 5
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
206010037660 Pyrexia Diseases 0.000 description 5
108020000999 Viral RNA Proteins 0.000 description 5
241000710772 Yellow fever virus Species 0.000 description 5
230000004075 alteration Effects 0.000 description 5
230000002238 attenuated effect Effects 0.000 description 5
238000010367 cloning Methods 0.000 description 5
208000025729 dengue disease Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
231100000350 mutagenesis Toxicity 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
238000003908 quality control method Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
229940051021 yellow-fever virus Drugs 0.000 description 5
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
101710144111 Non-structural protein 3 Proteins 0.000 description 4
208000004006 Tick-borne encephalitis Diseases 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
238000010804 cDNA synthesis Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
210000004748 cultured cell Anatomy 0.000 description 4
206010014599 encephalitis Diseases 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
229940113082 thymine Drugs 0.000 description 4
210000003501 vero cell Anatomy 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
101800001030 Non-structural protein 2A Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
101710172711 Structural protein Proteins 0.000 description 3
239000007984 Tris EDTA buffer Substances 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003746 feather Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000012239 gene modification Methods 0.000 description 3
230000005017 genetic modification Effects 0.000 description 3
235000013617 genetically modified food Nutrition 0.000 description 3
230000036512 infertility Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
JEOQACOXAOEPLX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1.OC(=O)[C@@H](N)CCCN=C(N)N JEOQACOXAOEPLX-WCCKRBBISA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000710829 Dengue virus group Species 0.000 description 2
206010014596 Encephalitis Japanese B Diseases 0.000 description 2
241000991587 Enterovirus C Species 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
206010053317 Hydrophobia Diseases 0.000 description 2
201000005807 Japanese encephalitis Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
241000710908 Murray Valley encephalitis virus Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
101800001020 Non-structural protein 4A Proteins 0.000 description 2
101800001019 Non-structural protein 4B Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
108010076039 Polyproteins Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
241000710771 Tick-borne encephalitis virus Species 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
108700002693 Viral Replicase Complex Proteins Proteins 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
LPSGONIDKRDQQM-CEOVSRFSSA-N 2-aminoacetic acid;(2s)-2-aminobutanedioic acid Chemical group NCC(O)=O.OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O LPSGONIDKRDQQM-CEOVSRFSSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101710117545 C protein Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241001625930 Luria Species 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100384355 Mus musculus Ctnnbip1 gene Proteins 0.000 description 1
PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
-1 NS2B Proteins 0.000 description 1
241001674048 Phthiraptera Species 0.000 description 1
208000032749 Pregnancy Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000004189 Salinomycin Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108030003004 Triphosphatases Proteins 0.000 description 1
101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
241000120645 Yellow fever virus group Species 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000004668 avian leukosis Diseases 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000005101 cell tropism Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000000991 chicken egg Anatomy 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
244000144992 flock Species 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108010071644 fragmentin Proteins 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000012768 mass vaccination Methods 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000005156 neurotropism Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000011017 operating method Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000013587 protein N-linked glycosylation Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000004513 sizing Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000007501 viral attachment Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

OA9800041A 1997-04-11 1998-04-09 Vaccines against infections caused by yf virus yf infectious cdna method for producing a recombinantyf virus from the yf infectious cdna and plasmids to assemble the yf infectious cdna OA10791A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
BRPI9701774A BRPI9701774B8 (pt)	1997-04-11	1997-04-11	cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.

Publications (1)

Publication Number	Publication Date
OA10791A true OA10791A (en)	2002-12-24

Family

ID=4066904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800041A OA10791A (en)	1997-04-11	1998-04-09	Vaccines against infections caused by yf virus yf infectious cdna method for producing a recombinantyf virus from the yf infectious cdna and plasmids to assemble the yf infectious cdna

Country Status (9)

Country	Link
US (2)	US6171854B1 (pt)
EP (1)	EP0877086B1 (pt)
BR (1)	BRPI9701774B8 (pt)
CA (1)	CA2233932C (pt)
CU (1)	CU22770A3 (pt)
DE (1)	DE69839169T2 (pt)
OA (1)	OA10791A (pt)
RU (1)	RU98106999A (pt)
ZA (1)	ZA982760B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6962708B1 (en) *	1997-02-28	2005-11-08	Acambis, Inc.	Chimeric flavivirus vaccines
BRPI9701774B8 (pt)	1997-04-11	2015-09-29	Fundação Oswaldo Cruz Fiocruz	cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
DE19757301A1 (de)	1997-12-22	1999-06-24	Deutsches Primatenzentrum Gmbh	Intra-nasale Gelbfieber-Impfung
US6541011B2 (en)	1998-02-11	2003-04-01	Maxygen, Inc.	Antigen library immunization
GB2372991B (en) *	2001-03-09	2004-11-17	Fiocruz Fundacao Oswaldo Cruz	Flavivirus expression vector
EP1401859B1 (en) *	2001-06-01	2013-08-07	Sanofi Pasteur Biologics Co.	Chimeric flavivirus vectors
US20050002968A1 (en) *	2002-01-15	2005-01-06	Monath Thomas P.	Flavivirus vaccines
JP2005519639A (ja)	2002-01-15	2005-07-07	アカンビスインコーポレーティッド	フラビウイルスワクチン
AU2003239932A1 (en) *	2002-05-31	2003-12-19	Acambis, Inc.	Tetravalent dengue vaccines
EP1375512B1 (en) *	2002-06-20	2009-07-22	Institut Pasteur	Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
WO2004009764A2 (en) *	2002-07-19	2004-01-29	Board Of Regents, The University Of Texas System	Methods and compositions concerning altered yellow fever virus strains
US7785799B2 (en) *	2002-08-16	2010-08-31	The Board Of Regents Of The University Of Texas System	Compositions and methods related to flavivirus envelope protein domain III antigens
KR101150584B1 (ko) *	2002-11-15	2012-06-27	사노피 파스테르 바이오로직스 씨오	웨스트 나일 바이러스 백신
ATE521627T1 (de)	2004-07-27	2011-09-15	Us Gov Health & Human Serv	Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
BRPI0504945B8 (pt)	2005-10-31	2022-08-02	Fundacao Oswaldo Cruz	Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
ATE475216T1 (de)	2006-06-30	2010-08-15	Abb Technology Ag	Hvdc-system und verfahren zur steuerung eines spannungsquellenumrichters in einem hvdc-system
US7872560B2 (en) *	2007-03-19	2011-01-18	Abc Taiwan Electronics Corp.	Independent planar transformer
EP1982727A1 (en) *	2007-04-17	2008-10-22	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Method for purification of viral proteins
HRP20191104T1 (hr)	2007-09-25	2019-09-20	Solubest Ltd.	Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
CN105944095B (zh)	2008-03-05	2021-04-02	赛诺菲巴斯德有限公司	一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (fr)	2008-07-09	2010-01-13	Sanofi Pasteur	Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2010008576A2 (en) *	2008-07-17	2010-01-21	Medigen, Inc.	Idna vaccines and methods for using the same
BRPI0904020B8 (pt)	2009-10-01	2021-05-25	Fundacao Oswaldo Cruz	composição vacinal contra o vírus da dengue, e, kit
BRPI0905645B8 (pt) *	2009-10-27	2021-05-25	Fundacao Oswaldo Cruz	vacina de dna contra o vírus da febre amarela
US11459619B2 (en)	2016-02-08	2022-10-04	The Johns Hopkins University	Handheld nucleic acid-based assay for rapid identification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4719177A (en)	1981-04-20	1988-01-12	Massachusetts Institute Of Technology	Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor
EP0872553B1 (en)	1991-09-19	2000-11-15	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES	Chimeric and/or growth-restricted flaviviruses
BRPI9701774B8 (pt)	1997-04-11	2015-09-29	Fundação Oswaldo Cruz Fiocruz	cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.

1997
- 1997-04-11 BR BRPI9701774A patent/BRPI9701774B8/pt not_active IP Right Cessation
1998
- 1998-04-01 ZA ZA982760A patent/ZA982760B/xx unknown
- 1998-04-07 CA CA002233932A patent/CA2233932C/en not_active Expired - Fee Related
- 1998-04-08 DE DE69839169T patent/DE69839169T2/de not_active Expired - Lifetime
- 1998-04-08 EP EP98106495A patent/EP0877086B1/en not_active Expired - Lifetime
- 1998-04-09 OA OA9800041A patent/OA10791A/en unknown
- 1998-04-10 RU RU98106999/13A patent/RU98106999A/ru not_active Application Discontinuation
- 1998-04-10 CU CU1998046A patent/CU22770A3/es unknown
- 1998-04-10 US US09/058,411 patent/US6171854B1/en not_active Expired - Lifetime
2000
- 2000-11-06 US US09/705,949 patent/US6589522B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BRPI9701774B8 (pt)	2015-09-29
RU98106999A (ru)	2000-02-20
BR9701774A (pt)	2000-08-01
CA2233932A1 (en)	1998-10-11
EP0877086B1 (en)	2008-02-27
ZA982760B (en)	1999-01-18
EP0877086A3 (en)	1999-09-01
EP0877086A2 (en)	1998-11-11
DE69839169T2 (de)	2009-03-19
US6171854B1 (en)	2001-01-09
BRPI9701774B1 (pt)	2015-08-25
CA2233932C (en)	2009-01-13
CU22770A3 (es)	2002-07-24
DE69839169D1 (de)	2008-04-10
US6589522B1 (en)	2003-07-08

Publication	Publication Date	Title
US6171854B1 (en)	2001-01-09	Yellow fever infectious cDNA and plasmids
JP3681358B2 (ja)	2005-08-10	キメラおよび／または増殖制限されたフラビウイルス
US8691550B2 (en)	2014-04-08	Vaccines against japanese encephalitis virus and west nile virus
US8088391B2 (en)	2012-01-03	West nile virus vaccine
US7569383B2 (en)	2009-08-04	Chimeric flavivirus vectors
JP6486827B2 (ja)	2019-03-20	デングウイルス血清型４（ｄｅｎ−４）構築物に関する核酸分子、組成物および使用
KR20090008193A (ko)	2009-01-21	가감염성 플라비바이러스 및 이들의 용도
CA2432370C (en)	2012-01-31	Attenuated flaviviral live vaccine comprising a capsid protein deletion
ES2287074T3 (es)	2007-12-16	Molecula de rna autorreplicante del virus de la hepatitis c.
US20030194801A1 (en)	2003-10-16	Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
AU2006338210A1 (en)	2007-08-23	RNA virus vaccines and methods
Nath et al.	2020	Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice
CN101084010B (zh)	2015-05-06	抗日本脑炎病毒及西尼罗病毒的疫苗
MXPA98002801A (en)	1999-05-31	Vaccines against infections caused by virus yf, infectious cdna of yf, method to produce a recombinant yf virus from the infectious cdna of yf and plasmides to gather the infectious cdna
HK1106723B (en)	2015-10-30	Vaccines against japanese encephalitis virus and west nile virus
HK1083192B (en)	2010-09-10	West nile virus vaccine